CTKB VS RDUS Stock Comparison

PerformanceTechnicalsEarningsProfitVolatilityAnalyst Price TargetsSentiment
PerformanceTechnicalsEarningsProfitVolatilityAnalyst Price TargetsSentiment

Performance

CTKB
10/100

CTKB returned -67.30% in the last 12 months. Based on SPY's performance of 9.73%, its performance is below average giving it a score of 10 of 100.

RDUS
10/100

RDUS returned -23.74% in the last 12 months. Based on SPY's performance of -13.67%, its performance is below average giving it a score of 10 of 100.

Technicals

CTKB
46/100

CTKB receives a 46 of 100 based on 14 indicators. 6 are bullish, 7 are bearish.

RDUS

"Technicals" not found for RDUS

Earnings

CTKB
43/100

CTKB has missed earnings 2 times in the last 20 quarters.

RDUS
10/100

RDUS has missed earnings 12 times in the last 20 quarters.

Profit

CTKB
38/100

Out of the last 15 quarters, CTKB has had 8 profitable quarters and has increased their profits year over year on 2 of them.

RDUS
19/100

Out of the last 20 quarters, RDUS has had 3 profitable quarters and has increased their profits year over year on 3 of them.

Volatility

CTKB
49/100

CTKB has had a lower than average amount of volatility over the last 12 months giving it a score of 49 of 100.

RDUS
40/100

RDUS has had a lower than average amount of volatility over the last 12 months giving it a score of 40 of 100.

Analyst Price Targets

CTKB

"Analyst Price Targets" not found for CTKB

RDUS
68/100

7 analysts offer 12-month price targets for RDUS. Together, they have an average target of 0, the most optimistic target put RDUS at 0 within 12-months and the most pessimistic has RDUS at 0.

Sentiment

CTKB

"Sentiment" not found for CTKB

RDUS
69/100

RDUS had a bullish sentiment score of 68.75% across Twitter and StockTwits over the last 12 months. It had an average of 2.25 posts, 0.00 comments, and 0.00 likes per day.

All score calculations are broken down here to help you make more informed investing decisions

Cytek Biosciences, Inc. Common Stock Summary

Nasdaq / CTKB
Healthcare
Medical - Devices
Cytek Biosciences, Inc., a cell analysis solutions company, provides cell analysis tools that facilitates scientific advances in biomedical research and clinical applications. It offers aurora and northern lights systems, which are spectrum flow cytometers that delivers cell analysis by utilizing the fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells; and aurora cell sorter system, which leverages full spectrum profiling technology to further broaden potential applications across cell analysis. The company also provides reagents and kits, including cFluor reagents, which are fluorochrome conjugated antibodies used to identify cells of interest for analysis on its instruments, as well as 25-color immunoprofiling assay that provides turnkey solutions for identifying major human immune subpopulations for TBNK cells, monocytes, dendritic cells, and basophils. In addition, it offers automated micro-sampling system and automated sample loader system, which are automated plate loaders to integrate seamlessly into the aurora and northern lights systems; SpectroFlo software that provides intuitive workflow from quality control to data analysis for aurora and northern lights systems; and customer support tools. The company serves pharmaceutical and biopharma companies, academic research centers, and clinical research organizations. It distributes its products through direct sales force and support organizations in North America, Europe, China, and the Asia-Pacific region; and through distributors or sales agents in European, Latin American, the Middle Eastern, and the Asia-Pacific countries. The company was formerly known as Cytoville, Inc. and changed its name to Cytek Biosciences, Inc. in August 2015. Cytek Biosciences, Inc. was founded in 1992 and is headquartered in Fremont, California.

Radius Recycling, Inc. Class A Common Stock Summary

Nasdaq / RDUS
Healthcare
Drug Manufacturers - Specialty & Generic
Radius Health, Inc., a biopharmaceutical company, focuses on addressing unmet medical needs in the areas of bone health, orphan diseases, and oncology. The company's commercial product is TYMLOS, an abaloparatide injection for the treatment of postmenopausal women with osteoporosis. It is also developing abaloparatide-SC, which is in Phase III clinical trials for the treatment of osteoporosis in men; abaloparatide-TD, a transdermal system that is in Phase III clinical trials to treat postmenopausal women with osteoporosis; Elacestrant (RAD1901), a selective estrogen receptor degrader, which is in Phase III clinical trials for the treatment of hormone-receptor positive breast cancer; and RAD011, which is in Phase II clinical trials for treatment of hyperphagia related to Prader-Willi syndrome. The company has collaborations and license agreements with 3M Company; Ipsen Pharma SAS; Teijin Limited; Berlin-Chemie AG; Eisai Co. Ltd.; and Duke University. Radius Health, Inc. was founded in 2003 and is headquartered in Boston, Massachusetts. As of August 10, 2022, Radius Health, Inc. was taken private.